Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

NCT01180959 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: Bevacizumab
DRUG: Erlotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]